✦ LIBER ✦

Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?

✍ Scribed by David Ahishakiye; Sophie Lorent; Daniel De Backer; Philippe Gottignies; Jean-Louis Vincent

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful Treatment with Drotrecogin al

✍ Heather D. Eppert; Kara B. Goddard; Crystal L. King 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB

Cost effectiveness analysis of drotrecog

✍ R Launois,L Riou Franca,B Guidet,P Aegerter,X Huet,P Meshaka… 📂 Article 📅 2002 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 1021 KB

Drotrecogin alfa (activated): current ev

✍ Mark D Williams,Jonathan M Janes,David R Nelson 📂 Article 📅 2006 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 72 KB

Protein C: a potential biomarker in seve

✍ Andrew F Shorr,David R Nelson,Duncan LA Wyncoll,Konrad Reinhart… 📂 Article 📅 2008 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 285 KB

The use of drotrecogin alfa recombinant

✍ Jennifer Weintraub; Thomas Satterwhite; Maria Allo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 97 KB

PIN30 COST-EFFECTIVENESS ANALYSIS OF DRO

✍ J Kuzma; P Kawalec; P Bochenski 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB